<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04687839</url>
  </required_header>
  <id_info>
    <org_study_id>RL3010A2019001</org_study_id>
    <nct_id>NCT04687839</nct_id>
  </id_info>
  <brief_title>Assessment of the Wound Healing Efficacy and Tolerance of a Medical Device on Wounds in Healthy Subjects.</brief_title>
  <official_title>Assessment of the Wound Healing Efficacy and Tolerance of the Medical Device RL3010A DP0378 on a Blister Suction Model in Healthy Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pierre Fabre Dermo Cosmetique</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pierre Fabre Dermo Cosmetique</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The tested medical device is indicated for the treatment of wounds and small skin injuries.&#xD;
      The intention of this study is to evaluate the tolerance and efficacy of the test product by&#xD;
      measuring the recovery of the skin barrier after wound produced by suction blister. But also,&#xD;
      by validating the accompanying physiological effect of the study product during this&#xD;
      recovery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 13, 2020</start_date>
  <completion_date type="Actual">August 17, 2020</completion_date>
  <primary_completion_date type="Actual">August 17, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of the tested product on the wound healing at D6</measure>
    <time_frame>Day6</time_frame>
    <description>By measuring the wound surface (measured by macro-photos) on treated area compared to an untreated area</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of the tested product on the cutaneous barrier restoration</measure>
    <time_frame>Day1, Day2, Day4, Day6, Day8(+/-1), Day10(+/-1) and Day13(+/-1)</time_frame>
    <description>By measuring the TEWL (Trans Epidermal Water Loss) on treated area compared to an untreated area</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of the tested product on healing</measure>
    <time_frame>Day1, Day2, Day4, Day6, Day8(+/-1), Day10(+/-1) and Day13(+/-1)</time_frame>
    <description>By measuring the wound surface (measured by macro-photos) on treated area compared to an untreated area</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance of the tested product</measure>
    <time_frame>Day1, Day2, Day4, Day6, Day8(+/-1), Day10(+/-1) and Day13(+/-1)</time_frame>
    <description>By measuring the occurence of adverse event</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Healthy adult subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>It's a randomized intra-individual comparative study with two injured study areas (treated and untreated) for each subject.&#xD;
The randomization will determine the application side on which the tested product will be applied (RIGHT or LEFT forearm).&#xD;
Twice daily application on the treated area.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Induction of suction blister</intervention_name>
    <description>For each subject, 2 superficial wounds will be made on the inner aspect of each forearm using the suction blister model.</description>
    <arm_group_label>Healthy adult subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Transepidermal water loss (TEWL)</intervention_name>
    <description>At V1, before blister suction use (T0) and after blister withdrawal before product application (T1)&#xD;
For subsequent visits, before product application</description>
    <arm_group_label>Healthy adult subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Macrophotography</intervention_name>
    <description>At V1, before blister suction use (T0) and after blister withdrawal before product application (T1)&#xD;
For subsequent visits, before product application</description>
    <arm_group_label>Healthy adult subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Wound healing medical device</intervention_name>
    <description>Twice daily application on superficial wounds</description>
    <arm_group_label>Healthy adult subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject with a phototype I, II or III according to the Fitzpatrick scale&#xD;
&#xD;
          -  Subject aged between 18 and 45 years included at selection visit&#xD;
&#xD;
          -  Subject with absence of infectious diseases (HIV and Hepatitis), confirmed by negative&#xD;
             blood test results&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of keloids and hypertrophic scars&#xD;
&#xD;
          -  Subject with removal of axillary lymph nodes&#xD;
&#xD;
          -  Pathology, active skin disease or dermatological condition in progress (psoriasis&#xD;
             and/or lichen ruber and/or eczema ...) or presence of dermatological lesions on the&#xD;
             inner side of the forearm (solar erythema or dermatosis ...) that may affect the&#xD;
             performance of the research or judged incompatible with the realization of the study&#xD;
&#xD;
          -  Subject with severe illness (severe infectious disease (e.g. severe flu)), chronic&#xD;
             disease or acute evolutionary pathology likely to influence the study results or&#xD;
             considered by the investigator hazardous for the subject or incompatible with the&#xD;
             study&#xD;
&#xD;
          -  Knowledge of Acquired Immunodeficiency Syndrome or Infectious (acute) Hepatitis&#xD;
&#xD;
          -  Subject presenting a healing pathology or a pathology with consequences on the healing&#xD;
             like the diabetes mellitus (type I and type II)&#xD;
&#xD;
          -  Subject with congenital methemoglobinemia or porphyria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kirstin Deuble-Bente, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kiebitzweg 2, 22869 Schenefeld/Hamburg, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr. Kirstin Deuble-Bente</name>
      <address>
        <city>Schenefeld</city>
        <zip>22869</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>September 2, 2020</study_first_submitted>
  <study_first_submitted_qc>December 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2020</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heaklthy adult subject</keyword>
  <keyword>Wound</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

